Director Higuchi John W. increased his direct ownership in Lipocine Inc. by purchasing 123,000 shares of the company's common stock on April 6, 2026. The transaction price was $2.05 per share, bringing the total consideration to $252,149. After the purchase, Higuchi directly holds 163,797 shares of Lipocine.
At the time of the filing, Lipocine's shares were trading at $1.94, close to the stock's 52-week low of $1.81. An internal analysis noted by InvestingPro characterized the stock as appearing undervalued at current levels and listed it among stocks considered most undervalued. An InvestingPro tip further highlighted that Lipocine's balance sheet shows more cash than debt, and subscribers are offered 15 additional exclusive tips.
The insider purchase comes after the company reported the outcome of a Phase 3 clinical trial for its postpartum depression candidate, LPCN 1154. According to the company update, LPCN 1154 did not meet the primary endpoint in the Phase 3 study, which enrolled 90 patients and measured effectiveness by comparing changes in the Hamilton Depression Rating Scale (HAM-D17) total score against placebo.
Despite the trial missing its primary endpoint, Lipocine emphasized that LPCN 1154 showed a positive safety profile. The company reported that adverse events observed during the study were mild to moderate in severity. The Phase 3 trial was conducted entirely in an outpatient setting, with completed patient visits and enrollment. Lipocine stated there were no reports of serious drug-related adverse events, and only one participant required a dose reduction due to an adverse event.
Following these trial developments, H.C. Wainwright raised its price target on Lipocine to $15.00 while maintaining a Buy rating. The firm cited trial progress, including completion of enrollment and dosing, as reasons for the price-target increase. Lipocine also reported that an independent safety review by the Data Safety Monitoring Board allowed the trial to continue without modification, noting the absence of treatment discontinuations or serious adverse events that would require alteration of the study.
For market participants, the transaction by a company director and the mixed clinical readout provide concurrent signals: insider buying at current prices and a regulatory and clinical picture that includes both a negative efficacy outcome on the primary endpoint and reassuring safety observations. The company's balance sheet note and the analyst action are additional context points cited by market commentary.
Investors seeking more granular guidance or additional tips referenced by InvestingPro would need access to the subscription service referenced in the company's filing and related commentary.